Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.54 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.54 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.54 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.54 |
| ▸ | MAPT | P10636 | 4/20 | 0.54 |
| ▸ | TP53 | P04637 | 2/20 | 0.50 |
| ▸ | HTT | P42858 | 2/20 | 0.50 |
| ▸ | CTSV | O60911 | 1/20 | 0.50 |
| ▸ | CTSL | P07711 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | MAOA | P21397 | 1/20 | 0.46 |
| ▸ | MAOB | P27338 | 1/20 | 0.46 |
| ▸ | MYC | P01106 | 1/20 | 0.45 |
| ▸ | MAX | P61244 | 1/20 | 0.45 |
| ▸ | AKR1C4 | P17516 | 1/20 | 0.44 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.44 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2997136 | 1.00 | ALDH1A1 (0.54) | ALDH1A1TDP1CYP3A4ALOX15MAPT | |
| SCHEMBL4095909 | 0.87 | ALDH1A1 (0.58) | ALDH1A1TDP1CYP3A4ALOX15MAPT | |
| SCHEMBL4095907 | 0.87 | ALDH1A1 (0.58) | ALDH1A1TDP1CYP3A4ALOX15MAPT | |
| SCHEMBL5864201 | 0.83 | ALDH1A1 (0.58) | ALDH1A1TDP1CYP3A4ALOX15MAPT | |
| SCHEMBL2887378 | 0.83 | ALDH1A1 (0.47) | ALDH1A1TDP1CYP3A4ALOX15MAPT | |
| SCHEMBL2887382 | 0.83 | ALDH1A1 (0.47) | ALDH1A1TDP1CYP3A4ALOX15MAPT | |
| SCHEMBL29528295 | 0.83 | MAPT (0.55) | ALDH1A1TDP1CYP3A4ALOX15MAPT | |
| SCHEMBL10061468 | 0.83 | MAPT (0.55) | ALDH1A1TDP1CYP3A4ALOX15MAPT | |
| SCHEMBL20558473 | 0.81 | TP53 (0.52) | ALDH1A1TDP1CYP3A4ALOX15MAPT | |
| SCHEMBL11622453 | 0.81 | MAPT (0.59) | ALDH1A1TDP1CYP3A4ALOX15MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120270859-A1 | INDOLINE DERIVATIVES AND THEIR USE IN TREATING DISEASE-STATES SUCH AS CANCER | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-10-25 | — | — | US | disclosed |
| US-8207179-B2 | Substituted indolines as tyrosine kinase inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-06-26 | — | — | US | disclosed |
| US-20100222331-A1 | NEW COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-09-02 | — | — | US | disclosed |
| US-20100184747-A1 | INDOLINE DERIVATIVES AND THEIR USE IN TREATING DISEASE-STATES SUCH AS CANCER | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-07-22 | — | — | US | disclosed |
| EP-2181108-A2 | 3-HETROCYCLYLIDENE-INDOLINONE DERIVATIVES AS INHIBITORS OF SPECIFIC CELL CYCLE KINASES | Boehringer Ingelheim International GmbH (DE) | 2010-05-05 | — | — | EP | disclosed |
| EP-2167465-A1 | INDOLINONE DERIVATIVES AND THEIR USE IN TREATING DISEASE-STATES SUCH AS CANCER | Boehringer Ingelheim International GmbH (DE) | 2010-03-31 | — | — | EP | disclosed |
| WO-2008152013-A1 | INDOLINONE DERIVATIVES AND THEIR USE IN TREATING DISEASE-STATES SUCH AS CANCER | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-12-18 | — | — | WO | disclosed |
| WO-2008152014-A2 | 3-HETROCYCLYLIDENE-INDOLINONE DERIVATIVES AS INHIBITORS OF SPECIFIC CELL CYCLE KINASES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-12-18 | — | — | WO | disclosed |
| US-5985909-A | Cyclopropylindoles and their seco precursors, and their use as prodrugs | CANCER RESEARCH CAMPAIGN TECHNOLOGY LIMITED (GB) | 1999-11-16 | — | — | US | disclosed |
| EP-0850220-A1 | CYCLOPROPYLINDOLES AND THEIR SECO PRECURSORS, AND THEIR USE AS PRODRUGS | AUCKLAND DIVISION CANCER SOCIETY OF NEW ZEALAND INC. (NZ) | 1998-07-01 | — | — | EP | disclosed |
| WO-1997007097-A1 | CYCLOPROPYLINDOLES AND THEIR SECO PRECURSORS, AND THEIR USE AS PRODRUGS | AUCKLAND DIVISION CANCER SOCIETY OF NEW ZEALAND INC. (NZ) | 1997-02-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120270859-A1 | INDOLINE DERIVATIVES AND THEIR USE IN TREATING DISEASE-STATES SUCH AS CANCER | IDO1, INMT, TPH1 | ALDH1A1 243/4885TDP1 733/4885CYP3A4 395/4885 |
| US-20100184747-A1 | INDOLINE DERIVATIVES AND THEIR USE IN TREATING DISEASE-STATES SUCH AS CANCER | IDO1, INMT, TPH1 | ALDH1A1 243/4885TDP1 733/4885CYP3A4 395/4885 |
| US-20100222331-A1 | NEW COMPOUNDS | CCNA1, CCNY, MKI67 | ALDH1A1 450/4885TDP1 1954/4885CYP3A4 1094/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.